Biogen forecasts annual profit above estimates as Leqembi sales pick up

Group 1 - Biogen forecasts 2026 profit exceeding Wall Street estimates, driven by demand for newer medicines and its Alzheimer's treatment Leqembi [1] - The company faces competition as older multiple sclerosis drugs encounter pressure from cheaper alternatives [1]